Literature DB >> 28763137

Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module.

Chase C Hansen1,2, Joshua B Smith1,3, Abdallah S R Mohamed1,4, Collin F Mulcahy1,5, Jeffrey S Wefel6, Katherine A Hutcheson7, Kelsey Chrane1,8, Jack Phan1, Steven J Frank1, Adam S Garden1, Blaine D Smith1,3, Hillary Eichelberger1,3, Carthal Anderson1,9, Colton McCoy1,2, Marina Horiates1,10, Conner Patrick1,9, Sarah Floris1,11, Chloe French1,3, Beth M Beadle1, William H Morrison1, Shirley Y Su7, Carol M Lewis7, Michael E Kupferman7, Jason M Johnson12, Heath D Skinner1, Stephen Y Lai7, Ehab Y Hanna7, David I Rosenthal1, Clifton D Fuller1,13, G Brandon Gunn1.   

Abstract

BACKGROUND: Using patient-reported and objective assessment tools, we sought to quantify cognitive symptoms and objective cognitive dysfunction in patients irradiated for skull base cancer.
METHODS: Participants were assessed using the Telephone Interview for Cognitive Status (TICS) and the MD Anderson Symptom Inventory-Head and Neck module (MDASI-HN), with subsequent analysis.
RESULTS: Of the 122 participants analyzed, the majority (63%) had no frank detectable cognitive impairment by TICS, with frank impairment in 6%. Overall, mean patient-reported problems with memory (MDASImemory ) was 3.3 (SD ±2.66). On recursive partition analysis, the MDASImemory cutoff point of ≥5 was associated with detectable cognitive impairment by TICS (logworth 1.69; P = .02), yet no MDASImemory threshold was associated with unambiguous absence of impairment by TICS.
CONCLUSION: Approximately one third of patients had ambiguous results by TICS assessment, for whom more rigorous testing may be warranted. Moderate to severe levels of patient-reported memory complaints on the MDASI-HN module may have utility as a screening tool for cognitive dysfunction in this population.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  cognitive impairment; memory; radiotherapy; skull base; symptoms

Mesh:

Year:  2017        PMID: 28763137      PMCID: PMC6082378          DOI: 10.1002/hed.24876

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  26 in total

1.  Neuropsychological function in adults after high dose fractionated radiation therapy of skull base tumors.

Authors:  G Glosser; P McManus; J Munzenrider; M Austin-Seymour; B Fullerton; J Adams; M M Urie
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-05-01       Impact factor: 7.038

2.  Evaluating the relationship between education level and cognitive impairment with the Montreal Cognitive Assessment Test.

Authors:  Esra Yancar Demir; Tuba Özcan
Journal:  Psychogeriatrics       Date:  2015-01-05       Impact factor: 2.440

3.  Cognitive function of patients with nasopharyngeal carcinoma with and without temporal lobe radionecrosis.

Authors:  M Cheung; A S Chan; S C Law; J H Chan; V K Tse
Journal:  Arch Neurol       Date:  2000-09

4.  Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module.

Authors:  David I Rosenthal; Tito R Mendoza; Mark S Chambers; Joshua A Asper; Ibrahima Gning; Merrill S Kies; Randal S Weber; Jan S Lewin; Adam S Garden; K Kian Ang; Xin S Wang; Charles S Cleeland
Journal:  Head Neck       Date:  2007-10       Impact factor: 3.147

5.  Neuropsychological function in patients with nasopharyngeal carcinoma after radiotherapy.

Authors:  M S Hua; S T Chen; L M Tang; W M Leung
Journal:  J Clin Exp Neuropsychol       Date:  1998-10       Impact factor: 2.475

Review 6.  Long-term sequelae of cancer treatment on the central nervous system in childhood.

Authors:  R J Packer; A T Meadows; L B Rorke; J L Goldwein; G D'Angio
Journal:  Med Pediatr Oncol       Date:  1987

7.  Progress of memory function after radiation therapy in patients with nasopharyngeal carcinoma.

Authors:  Linda C W Lam; S F Leung; Y L Chan
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2003       Impact factor: 2.198

8.  Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

Authors:  Minesh P Mehta; Patrick Rodrigus; C H J Terhaard; Aroor Rao; John Suh; Wilson Roa; Luis Souhami; Andrea Bezjak; Mark Leibenhaut; Ritsuko Komaki; Christopher Schultz; Robert Timmerman; Walter Curran; Jennifer Smith; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

Review 9.  Cognitive reserve.

Authors:  Yaakov Stern
Journal:  Neuropsychologia       Date:  2009-03-13       Impact factor: 3.139

10.  Psychological disorders, cognitive dysfunction and quality of life in nasopharyngeal carcinoma patients with radiation-induced brain injury.

Authors:  Yamei Tang; Donghua Luo; Xiaoming Rong; Xiaolei Shi; Ying Peng
Journal:  PLoS One       Date:  2012-06-11       Impact factor: 3.240

View more
  3 in total

1.  Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating.

Authors: 
Journal:  Radiother Oncol       Date:  2019-01-14       Impact factor: 6.280

2.  Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models.

Authors:  Limeng Wu; Sasa Vasilijic; Yao Sun; Jie Chen; Lukas D Landegger; Yanling Zhang; Wenjianlong Zhou; Jun Ren; Samuel Early; Zhenzhen Yin; William W Ho; Na Zhang; Xing Gao; Grace Y Lee; Meenal Datta; Jessica E Sagers; Alyssa Brown; Alona Muzikansky; Anat Stemmer-Rachamimov; Luo Zhang; Scott R Plotkin; Rakesh K Jain; Konstantina M Stankovic; Lei Xu
Journal:  Sci Transl Med       Date:  2021-07-14       Impact factor: 19.319

3.  Increased hippocampal TrkA expression ameliorates cranial radiation‑induced neurogenesis impairment and cognitive deficit via PI3K/AKT signaling.

Authors:  Shengjun Ji; Haohao Wu; Xin Ding; Qingqing Chen; Xing Jin; Jinming Yu; Ming Yang
Journal:  Oncol Rep       Date:  2020-09-28       Impact factor: 3.906

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.